Korean J Hematol.  2010 Jun;45(2):139-140. 10.5045/kjh.2010.45.2.139.

Is RARS-T a new disease entity or a subtype of RARS or ET?

• Bang SM

• KMID: 2083549
• DOI: http://doi.org/10.5045/kjh.2010.45.2.139

Abstract

No abstract available.

Reference

1. Jekarl DW, Han SB, Kim M, et al. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean J Hematol. 2010. 45:46–50.

2. Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol. 2009. 144:809–817.

3. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006. 108:3472–3476.

4. Juneja SK, Imbert M, Sigaux F, Jouault H, Sultan C. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983. 36:566–569.

5. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2 V617F mutation status identifies subtypes of refractory anaemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008. 93:34–40.